Primary |
Coronary Artery Disease |
40.0% |
Cardiac Failure Congestive |
20.0% |
Type 2 Diabetes Mellitus |
20.0% |
Hypercholesterolaemia |
13.3% |
Hypertension |
6.7% |
|
|
Secondary |
Product Used For Unknown Indication |
16.6% |
Coronary Artery Disease |
11.4% |
Acute Coronary Syndrome |
10.9% |
Hypertension |
10.4% |
Atrial Fibrillation |
4.7% |
Diabetic Retinopathy |
4.7% |
Myocardial Ischaemia |
4.7% |
Hypotension |
4.1% |
Renal Failure |
4.1% |
Bronchopneumonia |
3.6% |
Diabetes Mellitus |
3.6% |
Hyperlipidaemia |
3.6% |
Drug-induced Liver Injury |
3.1% |
Pyrexia |
3.1% |
Type 2 Diabetes Mellitus |
2.6% |
Sepsis |
2.1% |
Thrombosis Prophylaxis |
2.1% |
Anaemia |
1.6% |
Benign Prostatic Hyperplasia |
1.6% |
Cardiac Failure |
1.6% |
|
Cardiogenic Shock |
18.8% |
Duodenal Ulcer Haemorrhage |
18.8% |
Pulmonary Embolism |
12.5% |
Rectal Cancer |
12.5% |
Renal Failure Acute |
12.5% |
Shock Haemorrhagic |
12.5% |
Drug Prescribing Error |
6.3% |
Traumatic Haematoma |
6.3% |
|
Concomitant |
Product Used For Unknown Indication |
32.2% |
Hypertension |
12.0% |
Drug Use For Unknown Indication |
8.8% |
Parkinson's Disease |
5.2% |
Myocardial Ischaemia |
4.8% |
Prophylaxis |
4.6% |
Rheumatoid Arthritis |
4.5% |
Osteoporosis |
3.8% |
Type 2 Diabetes Mellitus |
3.2% |
Thrombosis Prophylaxis |
2.6% |
Cardiac Failure |
2.0% |
Glaucoma |
2.0% |
Hypercholesterolaemia |
2.0% |
Hyperlipidaemia |
2.0% |
Metabolic Disorder |
2.0% |
Ill-defined Disorder |
1.9% |
Hyperuricaemia |
1.7% |
Myeloma Recurrence |
1.7% |
Anticoagulant Therapy |
1.4% |
Ischaemia |
1.3% |
|
Death |
7.5% |
Ventricular Extrasystoles |
7.5% |
Vomiting |
7.5% |
Cardiac Failure |
6.3% |
Renal Failure Acute |
6.3% |
Sepsis |
6.3% |
Wegener's Granulomatosis |
6.3% |
Aortic Aneurysm |
5.0% |
Atrial Fibrillation |
5.0% |
Jaundice Cholestatic |
5.0% |
Myocardial Infarction |
5.0% |
Renal Failure |
5.0% |
Fall |
3.8% |
Hypertension |
3.8% |
Pain In Extremity |
3.8% |
Proctitis |
3.8% |
Pyrexia |
3.8% |
Urticaria |
3.8% |
Bronchopneumonia |
2.5% |
Cardiopulmonary Failure |
2.5% |
|